Menu
Menu
BOSTON, MA - September 22, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS’s AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway.
The PIK3CA/AKT1/PTEN pathway is a key molecular signaling network that regulates how cells grow and survive, and its disruption is linked to the development of many cancers, including breast and prostate cancer. The PTEN gene, when altered, can contribute to cancer development and resistance to treatment. As part of this collaboration, the companies have developed an optimized NGS solution that deploys AI agents to analyze and detect genomic mutations across the full PTEN gene. A prototype of the enhanced solution has already demonstrated improved sensitivity in its ability to detect complex mutations across the pathway.
As part of the agreement, SOPHiA GENETICS will roll out a Privileged Access Program to selected clinical laboratories specializing in breast and prostate cancer research to validate sensitivity in a real-world setting, with broader commercial availability expected in 2026, alongside a multi-center real-world evidence study to further test its effectiveness. SOPHiA GENETICS’s global network will also help drive adoption of advanced PIK3CA/AKT1/PTEN testing in both tissue and liquid biopsy to expand patient access to precision therapies.
“Each day brings new insights that transform our understanding of cancer. Partnering with innovative biopharma leaders like AstraZeneca allows us to translate these discoveries into action for breast and prostate cancer patients worldwide, representing another step forward in our mission to democratize data-driven medicine.” said Ross Muken, President, SOPHiA GENETICS.
The expanded partnership highlights the shared commitment of SOPHiA GENETICS and AstraZeneca to drive innovation in precision oncology and to ensure that patients across the globe can benefit from advanced genomic testing and targeted treatments. To learn more, connect with SOPHiA GENETICS at the World CB & CDx Summit in Boston, MA from September 22-25, 2025
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
